Welcome

to Visus

Pioneering novel ophthalmic and wound care therapies in large unaddressed markets

2.1 BILLION PEOPLE WILL BE AFFLICTED WITH PRESBYOPIA IN 2020
WITH APPROXIMATELY 123 MILLION PATIENTS IN THE USA ALONE
Founded in October 2019, our lead program is a fixed formulation eyedrop treatment for presbyopic patients.
It is estimated that 2.1 billion people will be afflicted with presbyopia this year, with about 123 million patients in the US. Current corrective options, including reading glasses and contact lenses, are burdensome and unacceptable to a large number of people.
Visus is preparing for late stage clinical trials for a once-a-day eyedrop treatment to greatly improve near vision in both phakic and pseudophakic patients.
The patent-protected Visus formulation has demonstrated a significant improvement in near visual acuity from five safety and efficacy studies, with three of these published.
We are excited to bring this therapy to market for the millions of adults globally who want to regain their near vision, without the need for reading glasses or contacts.